NEW YORK, April 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Mallinckrodt plc (NYSE: MNK), Amgen
Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard
Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ).
Private wealth members receive these notes ahead of publication. To
reserve complementary membership, limited openings are available
at: http://www.AnalystsReview.com/register
--
Mallinckrodt plc Analyst
Notes
On April 7, 2014, Mallinckrodt plc (Mallinckrodt) announced agreement to acquire
Questcor Pharmaceuticals, Inc. (Questcor) for approximately
$5.6 billion, in a move to boost its
specialty pharmaceuticals portfolio and gain access to Questcor's
high-growth H.P. Acthar Gel which generated sales of $761.3 million in 2013. The Board of Directors of
both the Companies approved the transaction, which is expected to
be completed in Q3 2014. As per the terms of the transaction,
Mallinckrodt will pay cash and stock
valued at $86.10 per share to
Questcor, which represents a premium of around 27% over Questcor's
close price as of April 4, 2014. Upon
completion of the merger, Mallinckrodt
shareholders will own approximately 50.5% and former Questcor
shareholders will own approximately 49.5% of the combined entity's
stock. Mallinckrodt, which also
recently acquired Cadence Pharmaceuticals in February 2014, expects the transaction to be
immediately accretive to its full-year 2014 adjusted diluted EPS,
and significantly accretive to its full-year 2015 adjusted diluted
EPS. The full analyst notes on Mallinckrodt plc are available to download free of
charge at:
http://www.AnalystsReview.com/04102014/MNK/report.pdf
--
Amgen Inc. Analyst Notes
On April 4, 2014, Amgen Inc.
(Amgen) announced top-line results from the primary overall
survival (OS) analysis of a Phase 3 trial in melanoma. The Company
informed that the OS analysis evaluated the efficacy and safety of
talimogene laherparepvec for the treatment of unresected stage
IIIB, IIIC or IV melanoma compared to treatment with subcutaneous
granulocyte-macrophage colony-stimulating factor (GM-CSF). As per
the results, the primary end point of durable response rate was met
(as previously reported), but the secondary endpoint of OS was not
met, although there was a strong trend in favor of talimogene
laherparepvec (p=0.051). "We remain encouraged that the study met
its primary endpoint of achieving durable responses in patients
with metastatic melanoma," said Sean E.
Harper, M.D., Executive Vice President of Research and
Development at Amgen. The full analyst notes on Amgen Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/AMGN/report.pdf
--
Express Scripts Inc. Analyst Notes
On April 8, 2014, Express Scripts
Holding Co. (Express Scripts), a U.S. based pharmacy benefit
manager, stepped up its efforts to stop the skyrocketing prices of
specialty drugs which now account for 28% of total spending on
drugs in U.S., Bloomberg reported. The report stated that Express
Scripts has criticized Gilead Sciences Inc. (Gilead) for pricing
its new hepatitis C drug Sovaldi as high as $84,000 for a 12-week course of treatment, or
$1,000 a day. The Company also plans
to ask its clients, comprising national employers, health insurance
plans and government agencies, to join a coalition that would stop
drug companies from resorting to such practices which, it believes,
will make pharmacy benefits unsustainable. Express Scripts' annual
Drug Trend Report revealed that spending on specialty drugs
increased 14% in 2013 and predicted it will leap another 63% by the
end of 2016 based mainly on prices for new pills to treat the 2.7
million Americans with hepatitis C. The full analyst notes on
Express Scripts Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04102014/ESRX/report.pdf
--
CR Bard Inc. Analyst Notes
On April 1, 2014, CR Bard Inc.
(Bard) announced that it will release its Q1 2014 financial results
on April 22, 2014, after the market
close, followed by a conference call at 5:00
p.m. EDT, to discuss the results, and to provide financial
guidance for Q2 2014. In the previous quarter (Q4 2013), the
Company reported a 3.8% increase in net sales to $791.3 million. Net income was reported at
$667.5 million, or $8.28 per diluted share. The full analyst notes
on CR Bard Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04102014/BCR/report.pdf
--
Jazz Pharmaceuticals plc Analyst Notes
On March 31, 2014, Jazz
Pharmaceuticals plc (Jazz Pharmaceuticals) and its majority owned
indirect subsidiary Gentium S.p.A. jointly announced the beginning
of the European commercial launch of Defitelio® (Defibrotide), the
first licensed product for the treatment of severe hepatic
veno-occlusive disease (severe VOD or sVOD) in patients over one
month of age undergoing haematopoietic stem cell transplantation
(HSCT) therapy. The duos have launched Defitelio in
Germany and Austria and expect to continue
the launch in 27 additional European countries on a rolling
basis during 2014 and 2015. According to the Companies, the
efficacy of Defitelio to treat sVOD in HSCT patients is supported
by data from a pivotal, multi-centre Phase 3 trial that evaluated
Defitelio for the treatment of sVOD compared with a historical
control group of patients who had received standard supportive
care. The full analyst notes on Jazz Pharmaceuticals plc are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/JAZZ/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review